After attending the 2026 federal summit on psychedelic medicine in Washington and watching this field enter a new level of public and political scrutiny following the White House executive order on psychedelic research and access, I started to develop a framework to navigate how to talk about the field of psychedelics.
Ten principles I came up with, organized around four questions: what approach do you bring, how precise is your language, what do you owe the patient, and how do you stay honest about what you don't yet know. I am sharing it to start a conversation. What are yours?
01. Bring healthy skepticism.
The research on psychedelic-assisted psychotherapy is genuinely promising. It is also still early. Most studies involve small sample sizes, specific populations, and controlled settings that do not always reflect real-world clinical conditions. Holding both of those things at once (the meaningful results and the limitations) is what responsible communication looks like in a field that is still developing its evidence base and has yet to build the real-world outcomes data needed to understand long-term effects at scale.
02. Hold the tensions.
This field sits at the intersection of ancestral traditions, emerging clinical science, and spiritual frameworks that do not always translate easily into research methodology. Many of these medicines have deep cultural roots; they have been used in ceremonial and healing contexts across different traditions long before they entered clinical trials. That cultural context matters and deserves to be named without being reduced to a clinical rationale or stripped of its meaning. There is also the tension between the subjective and the scientific: research is increasingly showing that mystical-type experiences, emotional breakthroughs, and moments of insight during sessions correlate with better outcomes. What patients describe in spiritual terms, science is beginning to measure. Those two frameworks do not always speak the same language, and that is worth acknowledging rather than flattening. And finally, the practical tension that does not have a clean resolution: the evidence base needs more time to mature, and people are suffering now and need access to care.
03. Name the molecule.
Ketamine, psilocybin, and MDMA have distinct pharmacological profiles, different bodies of evidence, different legal statuses, and different care contexts. Ketamine is FDA-approved and has decades of clinical use behind it. Psilocybin has shown meaningful results in trials for depression and end-of-life anxiety but remains a Schedule I substance federally. MDMA-assisted therapy for PTSD did not receive FDA approval in 2024, and the path forward is still being defined. Using "psychedelics" as a catch-all obscures those differences in ways that matter clinically, legally, and for patients trying to understand what is actually available to them.
04. Specify the care model.
Ketamine-assisted psychotherapy, a ketamine infusion clinic, at-home sublingual ketamine, and Spravato are four different treatment models with different structures, different levels of therapeutic support, and different evidence bases. Understanding those differences requires looking at several dimensions:
- The role of psychotherapy: whether it is structurally integrated into the treatment or left to the patient to arrange separately.
- Dose and intent: psycholytic doses, which are lower and used to facilitate talk therapy, versus psychedelic doses, which are higher and intended to produce a more immersive altered state experience.
- Set and setting: the mindset a patient brings into a session and the physical and relational environment in which it takes place, both of which have been shown to influence outcomes.
- Insurance coverage: ketamine-assisted psychotherapy and Spravato are more likely to be covered than IV infusions or at-home programs, which matters for who can realistically access each model.
The clinical container; who is present, what therapeutic support exists, how the experience is held before and after; is as significant as the medicine itself.
05. Understand the regulatory landscape precisely.
For both patients and clinicians, knowing which access pathways actually exist matters:
- FDA-approved pathways: Spravato is approved for treatment-resistant depression and administered in certified clinics. Ketamine is approved as an anesthetic and widely used off-label for depression and other psychiatric conditions. Expanded access, also known as compassionate use, is an existing FDA pathway that has been used to provide access to investigational compounds outside of clinical trials.
- Clinical trials: Multiple compounds are currently in Phase 2 and Phase 3 trials, including psilocybin for treatment-resistant depression and major depressive disorder. Following the White House executive order, the FDA issued Priority Review Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics, accelerating the timeline significantly. The Psychedelic Alpha clinical trials tracker is one of the most current public resources for following the pipeline.
- State pathways: Oregon and Colorado have established regulated therapeutic access programs for psilocybin. Several other states have decriminalized possession, which is a distinct category from legal therapeutic access.
- International access: Australia approved psilocybin and MDMA for therapeutic use in 2023. Some patients are traveling abroad to access treatments not yet available in the United States.
- Right to Try: The executive order directs the FDA to establish a pathway for eligible patients to access investigational psychedelics under the Right to Try Act. No patients are accessing treatments through this pathway yet.
06. Source the science.
When citing research, name the study, the institution, and the sample size. The field's credibility depends on people within it maintaining a higher standard than the coverage it receives. A claim presented without its source or its limitations is not clinical communication; it is marketing.
Not all research is equal, and in a field moving this fast, the distinction matters. A preprint is a study that has been posted publicly but has not yet been peer-reviewed; it has not been independently evaluated for methodology or accuracy. A peer-reviewed study has gone through that process and been published in a scientific journal. A randomized controlled trial (RCT) is considered the gold standard: participants are randomly assigned to treatment or control groups, which reduces bias. Open-label studies have no control group and both the patient and clinician know what treatment is being given, which can inflate results. Meta-analyses pool data across multiple studies and can offer stronger conclusions, but are only as good as the studies they draw from. When someone cites "the research," it is worth asking which kind.
07. Present psychedelic-assisted psychotherapy (PAP) as a treatment option for mental health.
Psychedelic-assisted psychotherapy starting with ketamine-assisted psychotherapy (KAP) is one option within a broader mental health landscape. SSRIs, psychiatric medication, talk therapy, lifestyle support (nutrition, movement, yoga), and conventional care remain valid pathways and for many patients, concurrent ones. KAP fits within this model as an integrative treatment that combines pharmacology and psychotherapy into a single coordinated intervention. Unlike daily antidepressants, ketamine-assisted psychotherapy (KAP) is administered intermittently and in a clinical context where the patient's subjective experience during treatment is part of the treatment itself. KAP is also part of a broader category known as interventional psychiatry, which includes TMS and ECT, which are targeted, time-limited approaches used across a range of clinical contexts. The goal is to give patients accurate information so they can make an informed decision, not to position one approach against another.
08. Give risks and benefits equal weight.
The evidence for psychedelic-assisted psychotherapy includes meaningful results across several indications: reductions in treatment-resistant depression, PTSD symptom relief, decreased anxiety in end-of-life contexts, and emerging data on addiction. Research also points to mechanisms that go beyond symptom relief, including neuroplasticity, increased psychological flexibility, and shifts in how patients relate to their own thoughts and emotions. At the same time, this treatment carries real risks. Contraindications exist. Medical and psychiatric screening is required. Difficult experiences during sessions do happen and in some cases are clinically significant. This treatment is not appropriate for everyone. Both sides of that picture belong in every conversation about this work.
09. Patient safety and rights are non-negotiable.
Patients are entitled to clear information about their diagnosis, the treatment plan, the risks, the benefits, and the alternatives, before, during, and after treatment. They have the right to know who is treating them, what their qualifications are, and what oversight exists. They have the right to withdraw consent at any point without consequence and to participate in treatment plan decisions. Clinicians have a parallel responsibility: to screen candidates thoroughly, to monitor vitals, and to have an emergency plan in place. Informed consent is not a form completed at intake. It is a continuous part of the therapeutic relationship, and upholding it is a clinical and ethical obligation. For a full overview of patient rights in psychedelic-assisted psychotherapy, see the Journey Clinical Patient Code of Conduct.
10. Stay current. Stay open.
The science, the policy, the legal landscape, and the clinical consensus in this field are all actively evolving. What was accurate last week may be incomplete today. Building that into how you communicate is part of speaking honestly about a field that is evolving in real time.
This field does not belong to any one discipline. It is being shaped by politicians and legislators, scientists and researchers, clinicians and care delivery operators, insurers, entrepreneurs, patients themselves, and the many people who believed in this work long before it had institutional support. Each brings a different perspective, and all of them are needed. What we say about this work, how we say it, and what we omit shapes who seeks care, who provides it, and how the field is regulated. A shared language is how we make that conversation possible.
Related Articles
- We Are at the Inflection Point for Psychedelic Medicine Reflections from the 2026 Psychedelic Medicine Coalition Federal Summit - National Press Club, Washington D.C.
- Journey Clinical Welcomes Federal Action to Accelerate Access to Evidence-Based Psychedelic Treatments
- Journey Clinical and Compass Pathways Announce Research Collaboration for Psilocybin Treatment Delivery
- Journey Clinical Launched a Nationwide KAP Therapist Directory — Here's Why It Matters
- Glossary of Ketamine-Assisted Psychotherapy (KAP)
For Therapists
Ready to bring ketamine-assisted psychotherapy into your practice? Learn how Journey Clinical supports licensed therapists with the medical infrastructure, collaborative care, insurance pathways, training, and community they need to offer KAP with confidence. Book a Demo →
For Patients
Looking for a psychedelic therapist near you? Browse our network of trained, licensed therapists offering ketamine-assisted psychotherapy across the country. Find a Therapist →